Effect of nafamostat mesylate anticoagulation and regional citrate anticoagulation during continuous renal replacement therapy in critically ill patients: a retrospective study of efficacy and safety
Open Access
- 4 November 2025
- journal article
- Published by Taylor & Francis in Renal Failure
- Vol. 47 (1) , 2580058
Abstract
Regional citrate anticoagulation (RCA) is recommended for critically ill patients at high bleeding risk undergoing continuous renal replacement therapy (CRRT). Nafamostat mesylate (NM), a short-half-life serine protease inhibitor, is a popular alternative in East Asia. Direct comparisons of their efficacy and safety are limited. This retrospective single-center study included 81 critically ill patients receiving CRRT with either NM (n = 31) or RCA (n = 50) from January 2022 to January 2023. The primary outcome was filter lifespan. Secondary outcomes included circuit patency, bleeding events, and metabolic complications. The median filter lifespan was significantly shorter in the NM group compared to the RCA group (23.4 vs. 29.6 h, p = 0.02). The NM group also had a higher rate of unplanned circuit discontinuation (52.3 vs. 39.1%, p = 0.03). Multivariable analysis confirmed RCA was independently associated with a lower risk of circuit failure (HR = 0.44, p = 0.03). Although not statistically significant, trends favored NM regarding metabolic safety, with lower incidences of severe metabolic alkalosis (16.1 vs. 36.0%, p = 0.09) and hypocalcemia (9.7 vs. 26.0%, p = 0.13). RCA demonstrated superior anticoagulation efficacy in prolonging filter survival, while NM may offer a more favorable metabolic safety profile. The choice of anticoagulant should be individualized based on efficacy priorities and metabolic risk.Keywords
Funding Information
- Center for Depression Research and Clinical Care, University of Texas Southwestern Medical Center (2020B1111170005)
This publication has 37 references indexed in Scilit:
- Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patientsKidney International, 2005
- Filter Run Time in CVVH: Pre- versus Post-Dilution and Nadroparin versus Regional Heparin-Protamine AnticoagulationBlood Purification, 2005
- Pre-Dilution vs. Post-Dilution during Continuous Veno-Venous Hemofiltration: Impact on Filter Life and Azotemic ControlNephron Clinical Practice, 2003
- The Influence of a Serine Protease Inhibitor, Nafamostat Mesilate, on Plasma Coagulation, and Platelet Activation during Experimental Extracorporeal Life Support (ECLS)Thrombosis and Haemostasis, 1998
- Impairment of citrate metabolism in acute hepatic failure.1997
- Inhibition of tissue factor-factor VIIa by nafamostat mesilate; a reply to the rebuttalThrombosis Research, 1995
- Effect of nafamostat mesilate, a synthetic protease inhibitor, on tissue factor-factor VIIa complex activityThrombosis Research, 1994
- Nafamostat Mesylate as Anticoagulant in Continuous Hemofiltration and Continuous Hemodiafiltration1991
- Inhibitory Effect of a New Synthetic Protease Inhibitor (FUT-175) on the Coagulation SystemPathophysiology of Haemostasis and Thrombosis, 1985
- New synthetic inhibitors of C1r̄, C1 esterase, thrombin, plasmin, kallikrein and trypsinBiochimica et Biophysica Acta (BBA) - Enzymology, 1981